These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36331316)

  • 21. Clinical potential of inclisiran for patients with a high risk of atherosclerotic cardiovascular disease.
    Nishikido T
    Cardiovasc Diabetol; 2023 Jan; 22(1):20. PubMed ID: 36717882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Renal Impairment, Cardiovascular Disease, and the Short-Term Efficacy and Safety of PCSK9 Targeted by Inclisiran.
    Zijlstra LE; Trompet S; Mooijaart SP; van Buren M; Jukema JW
    Mayo Clin Proc; 2020 Jan; 95(1):12-14. PubMed ID: 31902406
    [No Abstract]   [Full Text] [Related]  

  • 23. Inclisiran in dyslipidemia.
    Kosmas CE; Muñoz Estrella A; Sourlas A; Pantou D
    Drugs Today (Barc); 2021 May; 57(5):311-319. PubMed ID: 34061126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial.
    Leiter LA; Teoh H; Kallend D; Wright RS; Landmesser U; Wijngaard PLJ; Kastelein JJP; Ray KK
    Diabetes Care; 2019 Jan; 42(1):173-176. PubMed ID: 30487231
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inclisiran: A Novel Small Interfering RNA Drug for Low-Density Lipoprotein Reduction.
    Smith KW; White CM
    J Clin Pharmacol; 2022 Sep; 62(9):1079-1085. PubMed ID: 35279835
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inclisiran: a new milestone on the PCSK9 road to tackle cardiovascular risk.
    Santulli G; Jankauskas SS; Gambardella J
    Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):e11-e12. PubMed ID: 33655296
    [No Abstract]   [Full Text] [Related]  

  • 27. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9.
    Fitzgerald K; White S; Borodovsky A; Bettencourt BR; Strahs A; Clausen V; Wijngaard P; Horton JD; Taubel J; Brooks A; Fernando C; Kauffman RS; Kallend D; Vaishnaw A; Simon A
    N Engl J Med; 2017 Jan; 376(1):41-51. PubMed ID: 27959715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inclisiran-New hope in the management of lipid disorders?
    Dyrbuś K; Gąsior M; Penson P; Ray KK; Banach M
    J Clin Lipidol; 2020; 14(1):16-27. PubMed ID: 31879073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9-A Narrative Review.
    Merćep I; Friščić N; Strikić D; Reiner Ž
    Cardiovasc Ther; 2022; 2022():8129513. PubMed ID: 35237348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of inclisiran in South African patients at high cardiovascular risk: A subanalysis of the ORION phase III clinical trials.
    Raal F; Abelson M; Blignaut S; Burgess L; Coetzer S; Ebrahim I; Gibbon A; Jansen van Rensburg D; Jaros M; Lombard L; Van Nieuwenhuizen E; Pretorius M; Van Tonder A; Urbach D
    S Afr Med J; 2022 May; 112(6):426-432. PubMed ID: 36217872
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inclisiran: How Widely and When Should We Use It?
    Pirillo A; Catapano AL
    Curr Atheroscler Rep; 2022 Oct; 24(10):803-811. PubMed ID: 35877035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
    Ray KK; Wright RS; Kallend D; Koenig W; Leiter LA; Raal FJ; Bisch JA; Richardson T; Jaros M; Wijngaard PLJ; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1507-1519. PubMed ID: 32187462
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New hope for hyperlipidemia management: Inclisiran.
    Bandyopadhyay D; Hajra A; Ashish K; Qureshi A; Ball S
    J Cardiol; 2018 May; 71(5):523-524. PubMed ID: 29174841
    [No Abstract]   [Full Text] [Related]  

  • 34. [Update on PCSK9 inhibition].
    Katzmann JL; Custodis F; Schirmer SH; Laufs U
    Herz; 2022 Jun; 47(3):196-203. PubMed ID: 35445838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCSK9 inhibition: the dawn of a new age in cholesterol lowering?
    Preiss D; Mafham M
    Diabetologia; 2017 Mar; 60(3):381-389. PubMed ID: 28025677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inclisiran inhibits oxidized low-density lipoprotein-induced foam cell formation in Raw264.7 macrophages via activating the PPARγ pathway.
    Wang Z; Chen X; Liu J; Wang Y; Zhang S
    Autoimmunity; 2022 Jun; 55(4):223-232. PubMed ID: 35289693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
    Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP;
    N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inclisiran in lipid management: A Literature overview and future perspectives.
    Scicchitano P; Milo M; Mallamaci R; De Palo M; Caldarola P; Massari F; Gabrielli D; Colivicchi F; Ciccone MM
    Biomed Pharmacother; 2021 Nov; 143():112227. PubMed ID: 34563953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inclisiran (Leqvio) for LDL-cholesterol lowering.
    Med Lett Drugs Ther; 2022 Mar; 64(1646):43-45. PubMed ID: 35294427
    [No Abstract]   [Full Text] [Related]  

  • 40. Inclisiran creates unique opportunities and challenges for patient access to therapy: early experience in a United States Lipid Clinic.
    Chiou TT; Tomasi K; Taub PR; Wilkinson MJ
    J Clin Lipidol; 2023; 17(1):73-77. PubMed ID: 36371372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.